公开(公告)号：US20240084308A1

公开(公告)日：2024-03-14

申请号：US18495512

申请日：2023-10-26

Applicant: Monash University

Inventor： Siew Yeen Chai ,  Robert Widdop ,  Tracey Gaspari ,  Huey Wen Lee

IPC: C12N15/113 ,  A61K31/351 ,  A61K31/395 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/55 ,  A61P1/16 ,  A61P9/00 ,  A61P13/12

CPC classification number: C12N15/1137 ,  A61K31/351 ,  A61K31/395 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/55 ,  A61P1/16 ,  A61P9/00 ,  A61P13/12 ,  C12N2310/14

Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.

公开(公告)号：US20240082255A1

公开(公告)日：2024-03-14

申请号：US18507789

申请日：2023-11-13

Applicant: Board of Regents, The University of Texas System

Inventor： Manjeet Rao ,  Subapriya Rajamanickam ,  Santosh Timilsina ,  Virginia G. Kaklamani

IPC: A61K31/55 ,  A61K9/107 ,  A61K31/454 ,  A61K31/502 ,  A61K39/395 ,  A61P35/00 ,  A61P35/04

CPC classification number: A61K31/55 ,  A61K9/107 ,  A61K31/454 ,  A61K31/502 ,  A61K39/3955 ,  A61P35/00 ,  A61P35/04

Abstract: The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of imipramine.

公开(公告)号：US11912721B2

公开(公告)日：2024-02-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm MacCoss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07D491/08 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18 ,  C07F7/18 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55

CPC classification number: C07D519/00 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D471/18 ,  C07D487/08 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C07D493/18 ,  C07D495/08 ,  C07D495/18 ,  C07D513/18 ,  C07F7/1804

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US20240058328A1

公开(公告)日：2024-02-22

申请号：US18256721

申请日：2021-12-16

Applicant: AB SCIENCE

Inventor： Alain MOUSSY ,  Colin MANSFIELD

IPC: A61K31/496 ,  A61K31/44 ,  A61K31/27 ,  A61K31/55 ,  A61K31/13 ,  A61P25/28

CPC classification number: A61K31/496 ,  A61K31/44 ,  A61K31/27 ,  A61K31/55 ,  A61K31/13 ,  A61P25/28

Abstract: A 2-aminoarylthiazole derivative, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of less severe and/or early-stage Alzheimer's disease in a patient in need thereof. In particular, masitinib, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of Alzheimer's disease in a patient having a baseline ADCS-ADL (Alzheimer's Disease Cooperative Study—Activities of Daily Living) score equal to or greater, preferably greater than 32, having a baseline MMSE (Mini-Mental State Examination) score equal to or greater than 13, having a time from diagnosis to treatment initiation with masitinib, or a pharmaceutically acceptable salt or solvate thereof, equal to or less than 5 years, and/or having a baseline ADAS-Cog (Alzheimer's Disease Assessment Scale—Cognitive Subscale) score equal to or lower than 40.

公开(公告)号：US20240050510A1

公开(公告)日：2024-02-15

申请号：US18265933

申请日：2021-12-09

Applicant: The Open University

Inventor： Ravid DORON

IPC: A61K36/74 ,  A61K31/343 ,  A61K31/138 ,  A61K31/55 ,  A61K31/496 ,  A61P25/24 ,  A61P25/22 ,  A61K36/734

CPC classification number: A61K36/74 ,  A61K31/343 ,  A61K31/138 ,  A61K31/55 ,  A61K31/496 ,  A61P25/24 ,  A61P25/22 ,  A61K36/734

Abstract: The present invention concerns methods and compositions employing a combination of Uncaria rhynchophylla (UR) herb and an antidepressant or anxiolytic drug therapy for treating or preventing anxiety, stress, depression, and/or symptoms thereof, wherein the combined administration of UR and the drug elicit a fast on-set response in the subject.

公开(公告)号：US20240050454A1

公开(公告)日：2024-02-15

申请号：US18254705

申请日：2021-11-30

Applicant: Jeffrey Jewell ,  Mark Wingertzahn ,  WeSana Health Inc.

Inventor： Jeffrey Jewell ,  Mark Wingertzahn ,  Daniel Carcillo

IPC: A61K31/675 ,  A61K36/07 ,  A61K31/00 ,  A61K45/06 ,  A61K36/9066 ,  A61K36/185 ,  A61K31/55 ,  A61P25/24

CPC classification number: A61K31/675 ,  A61K36/07 ,  A61K31/658 ,  A61K45/06 ,  A61K36/9066 ,  A61K36/185 ,  A61K31/55 ,  A61P25/24

Abstract: As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating neurological conditions (e.g., traumatic brain injury or TBI), or symptoms thereof (e.g., anxiety or depression), with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., TBI), or symptoms thereof (e.g., anxiety or depression).

公开(公告)号：US20240033232A1

公开(公告)日：2024-02-01

申请号：US18275872

申请日：2021-03-10

Applicant: Wen TAN

Inventor： Wen TAN

IPC: A61K31/137 ,  A61K31/27 ,  A61K31/4704 ,  A61K31/24 ,  A61K31/44 ,  A61K31/538 ,  A61K31/55

CPC classification number: A61K31/137 ,  A61K31/27 ,  A61K31/4704 ,  A61K31/24 ,  A61K31/44 ,  A61K31/538 ,  A61K31/55

Abstract: This invention disclosed new use of (R)-enantiomer β2-agonists such as (R)-terbutaline and (R)-salbutamol in treatment of sepsis, sepsis related multiple organ failure and acute respiratory destress syndrome.

公开(公告)号：US20240024336A1

公开(公告)日：2024-01-25

申请号：US18367560

申请日：2023-09-13

Applicant: DemeRx, Inc.

Inventor： Emeline MAILLET ,  Lawrence FRIEDHOFF

IPC: A61K31/55

CPC classification number: A61K31/55

Abstract: A method for modulating tolerance to an opioid analgesic in a patient undergoing opioid analgesic therapy, the method comprising interrupting or administering concurrently with said opioid analgesic therapy an amount of ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof.

公开(公告)号：US11872227B2

公开(公告)日：2024-01-16

申请号：US17741146

申请日：2022-05-10

Applicant: ACETYLON PHARMACEUTICALS, INC.

Inventor： Brian North ,  Steven Quayle

IPC: A61K31/505 ,  A61P35/00 ,  A61K31/55

CPC classification number: A61K31/505 ,  A61K31/55 ,  A61P35/00

Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20230405124A1

公开(公告)日：2023-12-21

申请号：US18241549

申请日：2023-09-01

Applicant: OncoTracker, Inc.

Inventor： James Richard BERENSON

IPC: A61K45/00 ,  A61K31/18 ,  A61K31/5513 ,  A61K31/352 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/145 ,  A61K38/06 ,  A61P35/00 ,  A61K31/55 ,  A61K31/417 ,  A61K38/00 ,  A61K31/4164 ,  A61K31/27

CPC classification number: A61K45/00 ,  A61K31/18 ,  A61K31/5513 ,  A61K31/352 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/145 ,  A61K38/06 ,  A61P35/00 ,  A61K31/55 ,  A61K31/417 ,  A61K38/005 ,  A61K31/4164 ,  A61K31/27 ,  Y02A50/30

Abstract: The present invention provides methods of treating an immune system dysfunction or conditions associated with soluble BCMA using gamma secretase modulators or inhibitors in order to both restore immune function and improve the efficacy of therapies directed against BCMA present on the pathogenic B cell.